A INFLUÊNCIA DA TELOMERASE SOBRE O TELÔMERO NO DESENVOLVIMENTO DE LEUCEMIA
Schlagworte:
Leucemia, Telomerase, TelômeroAbstract
A leucemia é uma doença caracterizada pelo comprometimento das células hematopoiéticas que irão apresentar um telômero reduzido em detrimento da função ativada da enzima telomerase. Este estudo tem o intuito de descrever a influência da telomerase no processo de encurtamento do telômero e de senescência celular, e como estes contribuem para o surgimento do câncer, com enfoque na leucemia. Trata-se de uma Revisão Integrativa da Literatura. O estudo permitiu comprovar a relação existente entre o telômero e telomerase e o desenvolvimento da leucemia. Comprovou-se que células com telômeros que não sofrem encurtamento tendem a apresentar maiores probabilidades de anomalias genéticas e diferenciação para células cancerígenas.Downloads
Literaturhinweise
ABRALE.Leucemia. Disponível em: http://abrale.org.br/doencas/leucemia.
ALLEGRA, A. et al. Telomerase and telomere biology in hematological diseases: A new therapeutic target. Leukemia Research, v.56, pag.60-74. mai.2017.
BHAT, R. et al. Association od newly identified genetic variant rs2853677 of TERT with non-smal cell lung câncer and leucemia in population of Jammu and Kashmir, India. BMC Cancer, v.19, pag.493. mai.2019.
CALVELLO, C. et al. Alternative splicing of hTERT: a further mechanism for the controlo f active hTERT in acute myeloid leukemia. Leukemia & Lymphoma,v.59, pag.702-709. jul.2017.
ESKANDARI, E. et al. Leukocyte Telomere Length Shorthening, hTERT Genetic Polymorphisms and Risk of Childhood Acute Lyphoblastic Leukemia. Asian Pacif Journal of Cancer Prevention,v.19, p.1515-1521. jun.2018.
FIORINI, E; SANTONI, A; COLLA, S. Dysfunctional telomeres and hematological disorders. HHS Public Access, v.100, p.1-11. jan.2018.
GHASEMIMEHR, N. et al. The telomere inhibitor MST-312 synergistically enhances the apoptotic effect of doxorubicin in the pre- B acute lymphoblastic leucemia cells. Biomedicine and Pharmacotherapy, v.106, p.1742-1750. oct. 2018.
GUIÈZE, R. et al. Telomere status in chronic lymphocytic leujkemia with TP53 disruption. Oncotarget, v.7, n. 35. aug. 2016.
HANDA, H. et al. Human telomerase reverse transcriptase expression in a CD34-positive hematopoietic progenitor of myelodysplastic syndrome and acute myelogenous leucemia. Hematological Oncology, v.4, p.520-522. mai.2019.
HOFFBRAND A. V; MOSS P.H.A. Fundamentos em hematologia: 6. ed. Porto Alegre: Artmed, 2013.
INCA. Leucemia. Disponível em: https://www.inca.gov.br/tipos-de-cancer/leucemia.
LANSDORP, P. Maintenance of telomere length in ML. Blood Advences, v.25, p.2467-2472. nov.2017.
OLBERTOVA, H. et al. Telomere dynamics in adult hematological malignancies. Biomedical Papers, v.163, p.1-7. jan.2019.
PARK, H. et al. Dysregulation of Telomere Lengths and Telomerase Activity in Myelodysplastic Syndrome. Annals of Laboratory Medicine, v.37, p.195-203. fev.2017.
VASINA, D. et al. Apoptotic Endonuclease EndoG Inhibits Telomerase activity and Induces Malignant Transformation of Human CD4+ T Cells. Biochemistry (Moscow), v.82, p.24-37. jan.2018.
World Health Organization (WHO). Haematopoietic and lymphoid malignancies. In: International Agency for Ressearch on Cancer (IARC). World Cancer Report. Lyon: IARC; 2014. p. 703-722
WYSOCZANSKA, B. et al. Variability within the human TERT gene, telomere length and predisposition to chronic lymphocytic leucemia. Onco Targets and Therapy, v.12, p.4309-4320. mai.2019.
YUAN, X; LARSSON, C; XU, D. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players. Oncogene, v.34, p.6172-6183. ago.2019.
ZHANG, X. et al. Ageing and the telomere connection: Na intimate relationship with inflammation. Ageing Research Reviews, v.25, p.55-69. jan. 2016.